Cargando…
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917249/ https://www.ncbi.nlm.nih.gov/pubmed/33659205 http://dx.doi.org/10.3389/fonc.2020.575168 |
_version_ | 1783657657931923456 |
---|---|
author | Cottini, Francesca Huang, Ying Williams, Nita Bumma, Naresh Khan, Abdullah M. Chaudhry, Maria Devarakonda, Srinivas Efebera, Yvonne A. Benson, Don M. Rosko, Ashley E. |
author_facet | Cottini, Francesca Huang, Ying Williams, Nita Bumma, Naresh Khan, Abdullah M. Chaudhry, Maria Devarakonda, Srinivas Efebera, Yvonne A. Benson, Don M. Rosko, Ashley E. |
author_sort | Cottini, Francesca |
collection | PubMed |
description | Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients. |
format | Online Article Text |
id | pubmed-7917249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79172492021-03-02 Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Cottini, Francesca Huang, Ying Williams, Nita Bumma, Naresh Khan, Abdullah M. Chaudhry, Maria Devarakonda, Srinivas Efebera, Yvonne A. Benson, Don M. Rosko, Ashley E. Front Oncol Oncology Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients. Frontiers Media S.A. 2021-02-15 /pmc/articles/PMC7917249/ /pubmed/33659205 http://dx.doi.org/10.3389/fonc.2020.575168 Text en Copyright © 2021 Cottini, Huang, Williams, Bumma, Khan, Chaudhry, Devarakonda, Efebera, Benson and Rosko http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cottini, Francesca Huang, Ying Williams, Nita Bumma, Naresh Khan, Abdullah M. Chaudhry, Maria Devarakonda, Srinivas Efebera, Yvonne A. Benson, Don M. Rosko, Ashley E. Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title_full | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title_fullStr | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title_full_unstemmed | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title_short | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients |
title_sort | real world experience of daratumumab: evaluating lymphopenia and adverse events in multiple myeloma patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917249/ https://www.ncbi.nlm.nih.gov/pubmed/33659205 http://dx.doi.org/10.3389/fonc.2020.575168 |
work_keys_str_mv | AT cottinifrancesca realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT huangying realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT williamsnita realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT bummanaresh realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT khanabdullahm realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT chaudhrymaria realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT devarakondasrinivas realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT efeberayvonnea realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT bensondonm realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients AT roskoashleye realworldexperienceofdaratumumabevaluatinglymphopeniaandadverseeventsinmultiplemyelomapatients |